News

With the financing, KSQ will advance its first drug program into the clinic within the next 18 months and up to three additional oncology drug programs into IND-enabling

Libtayo is a fully-human monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein-1), and is claimed to be the first and only treatment specifically

EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet

The US Food and Drug Administration (FDA) approved Doptelet on May 21, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to

In November 2014, Janssen signed an exclusive worldwide collaboration and license agreement with Geron for the development and commercialization of imetelstat in oncology, including hematologic myeloid malignancies. Janssen

The initial consideration for the sale and transfer of the entire common stock of MTP US is $13.0 million, payable upon Closing, with up to $6m available by

The BLA for SB5 was submitted by Samsung Bioepis in July 2018. The BLA for SB5 was based on data derived from a randomized, double-blind 52-week Phase 3

Based in Boston of Massachusetts, Syntimmune is engaged in the development of differentiated drug candidates in a range of autoimmune diseases. As per terms of the deal, Alexion

Ibnsina Pharma, a major healthcare solutions provider in the region, has been growing steadily through supply chain services, importation, and distribution of health care products in the private